JP2018531021A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531021A5 JP2018531021A5 JP2018520106A JP2018520106A JP2018531021A5 JP 2018531021 A5 JP2018531021 A5 JP 2018531021A5 JP 2018520106 A JP2018520106 A JP 2018520106A JP 2018520106 A JP2018520106 A JP 2018520106A JP 2018531021 A5 JP2018531021 A5 JP 2018531021A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- anoikis
- inhibitors
- laminin
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 54
- 201000010099 disease Diseases 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 230000025164 anoikis Effects 0.000 claims description 36
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 34
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 34
- 210000002744 extracellular matrix Anatomy 0.000 claims description 34
- 239000002609 medium Substances 0.000 claims description 31
- 108010035532 Collagen Proteins 0.000 claims description 17
- 102000008186 Collagen Human genes 0.000 claims description 17
- 229920001436 collagen Polymers 0.000 claims description 17
- 108010085895 Laminin Proteins 0.000 claims description 16
- 102000007547 Laminin Human genes 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 239000001301 oxygen Substances 0.000 claims description 16
- 238000004113 cell culture Methods 0.000 claims description 14
- 108010067306 Fibronectins Proteins 0.000 claims description 13
- 102000016359 Fibronectins Human genes 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 13
- 108010028309 kalinin Proteins 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 230000037361 pathway Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000022131 cell cycle Effects 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- 229940043355 kinase inhibitor Drugs 0.000 claims description 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 6
- 229940123169 Caspase inhibitor Drugs 0.000 claims description 5
- -1 caspase inhibitor Substances 0.000 claims description 5
- 230000005660 hydrophilic surface Effects 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 4
- 102000019034 Chemokines Human genes 0.000 claims description 4
- 108010012236 Chemokines Proteins 0.000 claims description 4
- 102000018832 Cytochromes Human genes 0.000 claims description 4
- 108010052832 Cytochromes Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 230000010261 cell growth Effects 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 4
- 102000006495 integrins Human genes 0.000 claims description 4
- 108010044426 integrins Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 4
- 239000012679 serum free medium Substances 0.000 claims description 4
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 claims description 3
- 102100030416 Stromelysin-1 Human genes 0.000 claims description 3
- 102000042567 non-coding RNA Human genes 0.000 claims description 3
- 108091027963 non-coding RNA Proteins 0.000 claims description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 2
- 108090000312 Calcium Channels Proteins 0.000 claims description 2
- 102000003922 Calcium Channels Human genes 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 102000003846 Carbonic anhydrases Human genes 0.000 claims description 2
- 108090000209 Carbonic anhydrases Proteins 0.000 claims description 2
- 102000029816 Collagenase Human genes 0.000 claims description 2
- 108060005980 Collagenase Proteins 0.000 claims description 2
- 102000009058 Death Domain Receptors Human genes 0.000 claims description 2
- 108010049207 Death Domain Receptors Proteins 0.000 claims description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 102000015212 Fas Ligand Protein Human genes 0.000 claims description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 claims description 2
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 2
- 108010003272 Hyaluronate lyase Proteins 0.000 claims description 2
- 102000001974 Hyaluronidases Human genes 0.000 claims description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 claims description 2
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 2
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 2
- 108010059712 Pronase Proteins 0.000 claims description 2
- 239000005700 Putrescine Substances 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 2
- 102000004338 Transferrin Human genes 0.000 claims description 2
- 108090000901 Transferrin Proteins 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- 108090000631 Trypsin Proteins 0.000 claims description 2
- 102000004142 Trypsin Human genes 0.000 claims description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 claims description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010031318 Vitronectin Proteins 0.000 claims description 2
- 102100035140 Vitronectin Human genes 0.000 claims description 2
- 108050003627 Wnt Proteins 0.000 claims description 2
- 102000013814 Wnt Human genes 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000003305 autocrine Effects 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- 229960002424 collagenase Drugs 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 2
- 108010007093 dispase Proteins 0.000 claims description 2
- 235000020776 essential amino acid Nutrition 0.000 claims description 2
- 239000003797 essential amino acid Substances 0.000 claims description 2
- 229930182833 estradiol Natural products 0.000 claims description 2
- 229960005309 estradiol Drugs 0.000 claims description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 2
- 210000001808 exosome Anatomy 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 102000013361 fetuin Human genes 0.000 claims description 2
- 108060002885 fetuin Proteins 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 235000008191 folinic acid Nutrition 0.000 claims description 2
- 239000011672 folinic acid Substances 0.000 claims description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229960002773 hyaluronidase Drugs 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 229960001691 leucovorin Drugs 0.000 claims description 2
- 229950008325 levothyroxine Drugs 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 2
- 235000019136 lipoic acid Nutrition 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229910021645 metal ion Inorganic materials 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 239000003226 mitogen Substances 0.000 claims description 2
- 239000006179 pH buffering agent Substances 0.000 claims description 2
- 230000003076 paracrine Effects 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 claims description 2
- 239000000186 progesterone Substances 0.000 claims description 2
- 229960003387 progesterone Drugs 0.000 claims description 2
- 150000003212 purines Chemical class 0.000 claims description 2
- FCHXJFJNDJXENQ-UHFFFAOYSA-N pyridoxal hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(C=O)=C1O FCHXJFJNDJXENQ-UHFFFAOYSA-N 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 claims description 2
- 150000003230 pyrimidines Chemical class 0.000 claims description 2
- 229940076788 pyruvate Drugs 0.000 claims description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 2
- 239000006176 redox buffer Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229940082569 selenite Drugs 0.000 claims description 2
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 229960003604 testosterone Drugs 0.000 claims description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 2
- 229960002663 thioctic acid Drugs 0.000 claims description 2
- 229940104230 thymidine Drugs 0.000 claims description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims description 2
- 239000012581 transferrin Substances 0.000 claims description 2
- 229940035722 triiodothyronine Drugs 0.000 claims description 2
- 239000012588 trypsin Substances 0.000 claims description 2
- 239000002753 trypsin inhibitor Substances 0.000 claims description 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 2
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 229940047122 interleukins Drugs 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 150000004760 silicates Chemical class 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 230000003242 anti-anoikis Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021131632A JP2021175415A (ja) | 2015-10-20 | 2021-08-12 | 初代細胞試料を調製する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562243765P | 2015-10-20 | 2015-10-20 | |
| US62/243,765 | 2015-10-20 | ||
| PCT/US2016/057923 WO2017070353A1 (en) | 2015-10-20 | 2016-10-20 | Methods of preparing a primary cell sample |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131632A Division JP2021175415A (ja) | 2015-10-20 | 2021-08-12 | 初代細胞試料を調製する方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018531021A JP2018531021A (ja) | 2018-10-25 |
| JP2018531021A6 JP2018531021A6 (ja) | 2018-12-13 |
| JP2018531021A5 true JP2018531021A5 (enExample) | 2019-10-10 |
| JP7202613B2 JP7202613B2 (ja) | 2023-01-12 |
Family
ID=57233884
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018520106A Active JP7202613B2 (ja) | 2015-10-20 | 2016-10-20 | 初代細胞試料を調製する方法 |
| JP2021131632A Pending JP2021175415A (ja) | 2015-10-20 | 2021-08-12 | 初代細胞試料を調製する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131632A Pending JP2021175415A (ja) | 2015-10-20 | 2021-08-12 | 初代細胞試料を調製する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11591573B2 (enExample) |
| EP (1) | EP3365436B1 (enExample) |
| JP (2) | JP7202613B2 (enExample) |
| KR (1) | KR102757122B1 (enExample) |
| CN (1) | CN108138146A (enExample) |
| AU (1) | AU2016341938B2 (enExample) |
| CA (1) | CA2999054A1 (enExample) |
| DK (1) | DK3365436T3 (enExample) |
| WO (1) | WO2017070353A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2999054A1 (en) | 2015-10-20 | 2017-04-27 | Celcuity Llc | Methods of preparing a primary cell sample |
| CN108300688B (zh) * | 2018-02-07 | 2021-02-02 | 上海赛立维生物科技有限公司 | 原代肝细胞分离和培养方法 |
| CN109402051A (zh) * | 2018-12-28 | 2019-03-01 | 青岛麦迪赛斯生物科技有限公司 | 一种人脐带间充质干细胞无血清培养基 |
| CN109777736B (zh) * | 2019-01-29 | 2022-03-25 | 美闺(长沙)医疗美容有限公司 | 一种活细胞分析设备及方法 |
| CN109943520B (zh) * | 2019-03-08 | 2023-06-23 | 中国人民解放军军事科学院军事医学研究院 | 汗腺细胞的分离和培养获得汗腺类器官的方法及其应用 |
| WO2021119056A1 (en) | 2019-12-09 | 2021-06-17 | Celcuity Inc. | Methods of treating cancer patients with ras node or rtk targeted therapeutic agents |
| CN111733136B (zh) * | 2020-06-29 | 2021-11-30 | 中山大学孙逸仙纪念医院 | 一种提高CD90posi细胞分离效率的方法 |
| JP7452764B2 (ja) | 2021-10-27 | 2024-03-19 | 住友ベークライト株式会社 | ステータ及び構造体 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995018216A1 (en) | 1993-12-30 | 1995-07-06 | Nitta Gelatin Inc. | Process for embedding culture of animal cells |
| US5858678A (en) | 1994-08-02 | 1999-01-12 | St. Louis University | Apoptosis-regulating proteins |
| US8252591B2 (en) | 2004-05-07 | 2012-08-28 | Whitehead Institute For Biomedical Research | Hormone responsive tissue culture system and uses thereof |
| ATE527341T1 (de) | 2004-10-27 | 2011-10-15 | Univ Bruxelles | Hepatische differenzierung von stammzellen |
| FR2894594B1 (fr) * | 2005-12-12 | 2008-02-08 | Univ Limoges | Test predictif de reponse therapeutique du cancer du sein |
| ES2535929T3 (es) * | 2007-11-20 | 2015-05-19 | Hopitaux Universitaires De Genève | Métodos para identificar, purificar y enriquecer células madre o inmaduras de inicio de cáncer a partir de tumores y uso de las mismas |
| US9096827B2 (en) | 2008-09-02 | 2015-08-04 | Pluristem Ltd. | Adherent cells from placenta tissue and use thereof in therapy |
| WO2011090068A1 (ja) | 2010-01-19 | 2011-07-28 | 株式会社Ｒｅｉメディカル | 癌組織由来細胞塊または癌細胞凝集塊の培養方法、評価方法および保存方法 |
| CN103025887A (zh) | 2010-05-03 | 2013-04-03 | 麦克罗斯特姆公司 | 筛选方法、由其确定的组合物、可用于其确定的工具和由其生产的细胞群 |
| TWI477599B (zh) | 2011-01-28 | 2015-03-21 | Hon Hai Prec Ind Co Ltd | 培育基體 |
| PT2764099T (pt) * | 2011-10-04 | 2018-02-28 | Mitra Rxdx India Private Ltd | Composição de ecm, plataforma de microambiente tumoral e seus métodos |
| US20130330761A1 (en) | 2012-06-12 | 2013-12-12 | Celcuity, LLC | Whole cell assays and methods |
| US20140142000A1 (en) | 2012-10-25 | 2014-05-22 | Academia Sinica | Microfluidic array platform for simultaneous cell culture under oxygen tensions |
| CA2895791A1 (en) | 2013-01-25 | 2014-07-31 | Xcell Biosciences, Inc. | Methods, compositions, kits, and systems for selective enrichment of target cells |
| GB201303491D0 (en) | 2013-02-27 | 2013-04-10 | Cancer Rec Tech Ltd | Culture of leukemia initiating cells |
| WO2015089380A2 (en) * | 2013-12-12 | 2015-06-18 | Celcuity Llc | Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent |
| WO2015156929A1 (en) * | 2014-04-07 | 2015-10-15 | The Trustees Of Columbia University In The City Of New York | Method for culture of human bladder cell lines and organoids and uses thereof |
| CA2999054A1 (en) * | 2015-10-20 | 2017-04-27 | Celcuity Llc | Methods of preparing a primary cell sample |
-
2016
- 2016-10-20 CA CA2999054A patent/CA2999054A1/en active Pending
- 2016-10-20 WO PCT/US2016/057923 patent/WO2017070353A1/en not_active Ceased
- 2016-10-20 DK DK16791191.6T patent/DK3365436T3/da active
- 2016-10-20 CN CN201680061008.6A patent/CN108138146A/zh active Pending
- 2016-10-20 KR KR1020187010765A patent/KR102757122B1/ko active Active
- 2016-10-20 JP JP2018520106A patent/JP7202613B2/ja active Active
- 2016-10-20 EP EP16791191.6A patent/EP3365436B1/en active Active
- 2016-10-20 AU AU2016341938A patent/AU2016341938B2/en not_active Ceased
-
2018
- 2018-04-11 US US15/950,739 patent/US11591573B2/en active Active
-
2021
- 2021-08-12 JP JP2021131632A patent/JP2021175415A/ja active Pending
-
2023
- 2023-01-23 US US18/100,437 patent/US12215356B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531021A5 (enExample) | ||
| US11980641B2 (en) | Methods for generation of podocytes from pluripotent stem cells and cells produced by the same | |
| US11680246B2 (en) | Ex vivo proliferation of epithelial cells | |
| CN114174493B (zh) | 使用带电表面从诱导多能干细胞产生多个谱系的方法 | |
| JP6949336B2 (ja) | 人工多能性幹細胞由来腸管幹細胞の維持培養 | |
| EP3892718A1 (en) | Ex vivo proliferation of epithelial cells | |
| US20180051258A1 (en) | Ex vivo proliferation of epithelial cells | |
| JP2011206064A5 (enExample) | ||
| TWI438275B (zh) | 促進幹細胞分化為胰島素製造細胞的方法 | |
| JP6677648B2 (ja) | 細胞の増殖及び多能性の調節 | |
| CN111690595A (zh) | 一种无血清无饲养层的胚胎干细胞或多能干细胞培养基及其应用 | |
| CN112608884B (zh) | 培养基补充组合物、干细胞培养基及其制备方法 | |
| EP3384011A1 (en) | Methods for differentiating cells into hepatic stellate cells | |
| CN114369577A (zh) | 牛诱导扩展多能性成体干细胞、建系方法及培养液 | |
| KR101833960B1 (ko) | 정원줄기세포의 3차원 체외 배양 방법 및 그 용도 | |
| WO2024016058A1 (en) | Engineered human cardiac tissue | |
| Choi et al. | Inhibition of BMP-mediated SMAD pathway supports the pluripotency of pig embryonic stem cells in the absence of feeder cells | |
| EP4495229A1 (en) | Medium composition for culturing porcine pluripotent stem cells | |
| JP7058330B2 (ja) | 腸管上皮細胞の製造方法および腸管上皮細胞 | |
| WO2025018366A1 (ja) | 腸管上皮細胞を作製する方法 | |
| CN116478914A (zh) | 无血清细胞培养体系及其细胞消化终止液 | |
| Bazer et al. | Select nutrients and glucose transporters in pig uteri and conceptuses. | |
| EP4565677A2 (en) | Bovine trophoblast stem cells and uses thereof | |
| HK1249919B (en) | Ex vivo proliferation of epithelial cells |